Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.66 |
| ▸ | GHSR | Q92847 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507360 | 0.96 | OPRM1 (0.67) | OPRM1OPRD1GHSRACEECE1 | |
| SCHEMBL30051359 | 0.95 | ACE (0.64) | OPRM1OPRD1GHSRKDM4EMAPT | |
| SCHEMBL30052393 | 0.92 | OPRM1 (0.66) | OPRM1OPRD1GHSRKDM4EMAPT | |
| SCHEMBL30288025 | 0.92 | KMT2A (0.64) | OPRM1OPRD1GHSRKDM4EMAPT | |
| SCHEMBL30052812 | 0.92 | KMT2A (0.64) | OPRM1OPRD1GHSRKDM4EMAPT | |
| SCHEMBL9499905 | 0.92 | KDM4E (0.70) | OPRM1OPRD1KDM4EMAPTMEN1 | |
| SCHEMBL7778685 | 0.92 | KDM4E (0.70) | OPRM1OPRD1KDM4EMAPTMEN1 | |
| SCHEMBL7781160 | 0.92 | KDM4E (0.70) | OPRM1OPRD1KDM4EMAPTMEN1 | |
| SCHEMBL11580346 | 0.92 | KDM4E (0.70) | OPRM1OPRD1KDM4EMAPTMEN1 | |
| SCHEMBL1617917 | 0.92 | KDM4E (0.70) | OPRM1OPRD1KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025042352-A2 | SINGLE-CHAIN VARIABLE FRAGMENT (SCFV) MOUSE ANTIBODY SPECIFIC TO SAPOSIN-LIKE PROTEIN 2 OF THE LIVER FLUKE FASCIOLA GIGANTICA | BURAPHA UNIVERSITY (TH) | 2025-02-27 | — | — | WO | claimed |
| CN-115397247-B | Fermented milk, process for producing the same, and dephosphorized yogurt | GODO SHUSEI Co.,Ltd. (JP) | 2026-05-26 | — | — | CN | disclosed |
| CN-114080232-B | Extracellular vesicles for vaccine delivery | Lhasa Sales Co.,Ltd. (CH) | 2026-05-26 | — | — | CN | disclosed |
| CN-115925917-B | Anti-PVRIG protein antibodies or antibody fragments and uses thereof | 合肥天港免疫药物有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-114846026-B | Multispecific antibodies with binding specificity for human IL-13 and IL-17 | UCB生物制药有限责任公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-116583298-B | PD-1 targeted IL-15/IL-15RαFC fusion proteins with improved properties | 基因泰克公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250222090-A1 | TUBERCULOSIS VACCINES | THE JOHNS HOPKINS UNIVERSITY | 2025-07-10 | — | — | US | disclosed |
| CN-115785268-B | Anti-CD 47 antibodies and uses thereof | 三优生物医药(上海)有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-111670199-B | Monoclonal antibody NEO-201 for treating human carcinoma | 精密生物制品股份有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-114008069-A | Compositions of exosomes and AAV | 科迪亚克生物科学公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114008207-A | Improved gene editing system | 中国科学院遗传与发育生物学研究所 | 2022-02-01 | — | — | CN | disclosed |
| CN-114002427-A | Method and kit for detecting novel coronavirus antigen | 北京健乃喜生物技术有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113993989-A | Process for producing ergothioneine | 丹麦科技大学 | 2022-01-28 | — | — | CN | disclosed |
| CN-111116743-B | Hsp90 antibodies and their use against fungal infections | 迈威(上海)生物科技股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113993550-A | Conditioning method for gene therapy | 美真达治疗公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113980129-A | Group of IL-11 monoclonal antibodies and medical application thereof | 东大生物技术(苏州)有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-107206072-B | Combination therapy of the T cell activating bispecific antigen binding molecule CD3 ABD folate receptor 1(FolR1) and a PD-1 axis binding antagonist | 豪夫迈·罗氏有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113956358-A | anti-TIGIT antibodies and methods of use | 豪夫迈·罗氏有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-109666657-B | Glucose oxidase for improving heat resistance | 东莞泛亚太生物科技有限公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | OPRM1 804/4885OPRD1 402/4885GHSR 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.